At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 18 enrolled
Drug / intervention
Talimogene laherparepvecdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Multi-center, Open-Label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma
In Brief
A Phase 1 clinical trial evaluating Talimogene laherparepvec for Unresectable Stage IIIB-IV Malignant Melanoma. Completed, enrolled 18 participants across 9 sites.
Detailed Summary
There are 2 fold of purposes for this study. 1 is to evaluate safety and tolerability and the other is to study the anti-tumor effects of talimogene laherparepvec in Japanese participants with unresectable stage IIIB-IV malignant melanoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 2017
Enrollment StartMar 2017
Primary CompletionAug 2020
Study CompletionJan 2023
TodayJul 2026
First PostedFeb 27, 2017
Enrollment StartMar 7, 2017
Primary CompletionAug 3, 2020
Study CompletionJan 12, 2023
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 9.3 years ago
Interventions
Talimogene laherparepvecdrug
Talimogene laherparepvec will be administered as an intralesional injection.